Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322:746–55.
Ni X, Li Z, Li X, Zhang X, Bai G, Liu Y, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study. Lancet. 2022;400:1020–32.
Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–53.
Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307:1062–71.
Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4.
Reshetnyak AV, Rossi P, Myasnikov AG, Sowaileh M, Mohanty J, Nourse A, Miller DJ, Lax I, Schlessinger J, Kalodimos CG. Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature. 2021;600:153–7.
Lin L, Miao L, Lin H, Cheng J, Li M, Zhuo Z, et al. Targeting RAS in neuroblastoma: is it possible? Pharmacol Ther. 2022;236:108054.
Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–93.
Lagmay JP, London WB, Gross TG, Termuhlen A, Sullivan N, Axel A, et al. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009;15:5234–9.
Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mosse YP, Kim C, Diskin SJ, Cole KA, Bosse K, Diamond M, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41:718–23.
Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, McDaniel LD, Diamond M, Hart LS, Zhu S, Durbin AD, Abraham BJ, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015;528:418–21.
Zhuo ZJ, Liu W, Zhang J, Zhu J, Zhang R, Tang J, et al. Functional polymorphisms at ERCC1/XPF genes confer neuroblastoma risk in Chinese children. EBioMedicine. 2018;30:113–9.
Li J, Zhang H, Wang H. N1-methyladenosine modification in cancer biology: current status and future perspectives. Comput Struct Biotechnol J. 2022;20:6578–85.
Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024;23:130.
Bar-Yaacov D, Frumkin I, Yashiro Y, Chujo T, Ishigami Y, Chemla Y, et al. Mitochondrial 16s rRNA is methylated by tRNA methyltransferase TRMT61B in all vertebrates. PLoS Biol. 2016;14:e1002557.
Howell NW, Jora M, Jepson BF, Limbach PA, Jackman JE. Distinct substrate specificities of the human tRNA methyltransferases TRMT10A and TRMT10B. RNA. 2019;25:1366–76.
Anderson J, Phan L, Hinnebusch AG. The Gcd10p/Gcd14p complex is the essential two-subunit tRNA(1-methyladenosine) methyltransferase of Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 2000;97:5173–8.
Li X, Xiong X, Wang K, Wang L, Shu X, Ma S, et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat Chem Biol. 2016;12:311–6.
Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D, Erlacher M, Rossmanith W, Stern-Ginossar N, Schwartz S. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017;551:251–5.
Dai X, Wang T, Gonzalez G, Wang Y. Identification of YTH domain-containing proteins as the readers for N1-methyladenosine in RNA. Anal Chem. 2018;90:6380–4.
Shi L, Chen W, Zhang Z, Chen J, Xue M. N1-methyladenosine profiling of long non-coding RNA in colorectal cancer. IUBMB Life. 2021;73:1235–43.
Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim MS, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016;530:441–6.
Zhang LS, Xiong QP, Pena Perez S, Liu C, Wei J, Le C, et al. ALKBH7-mediated demethylation regulates mitochondrial polycistronic RNA processing. Nat Cell Biol. 2021;23:684–91.
Richter U, Evans ME, Clark WC, Marttinen P, Shoubridge EA, Suomalainen A, et al. RNA modification landscape of the human mitochondrial tRNA(Lys) regulates protein synthesis. Nat Commun. 2018;9:3966.
Li L, Tan H, Zhou J, Hu F. Predicting response of immunotherapy and targeted therapy and prognosis characteristics for renal clear cell carcinoma based on m1A methylation regulators. Sci Rep. 2023;13:12645.
Zeng D, Zhu J, Li J, Liao F, Yang Z, Li Y, et al. TRMT61B rs4563180 G > C variant reduces hepatoblastoma risk: a case-control study of seven medical centers. Aging. 2023;15:7583–92.
Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, et al. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12:6314.
Li H, Zhang Y, Guo Y, Liu R, Yu Q, Gong L, et al. ALKBH1 promotes lung cancer by regulating m6A RNA demethylation. Biochem Pharmacol. 2021;189:114284.
Rashad S, Han X, Sato K, Mishima E, Abe T, Tominaga T, Niizuma K. The stress specific impact of ALKBH1 on tRNA cleavage and TiRNA generation. RNA Biol. 2020;17:1092–103.
Chang J, Lin L, Zhang W, Yang J, Zhang M, Yin H, Zhang X, Zhou C, Zou Y, He J. Genetic variants of m1A modification genes and the risk of neuroblastoma: novel insights from a Chinese case-control study. Hum Genomics. 2025;19:50.
Zhuo Z, Lu H, Zhu J, Hua RX, Li Y, Yang Z, et al. METTL14 gene polymorphisms confer neuroblastoma susceptibility: an eight-center case-control study. Mol Ther Nucleic Acids. 2020;22:17–26.
He J, Yuan L, Lin H, Lin A, Chen H, Luo A, Zhuo Z, Liu X. Genetic variants in m(6)A modification core genes are associated with glioma risk in Chinese children. Mol Ther Oncolytics. 2021;20:199–208.
Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised neuroblastoma risk classification system: a report from the children’s oncology group. J Clin Oncol. 2021;39:3229–41.
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–17.
Tang Q, Li L, Wang Y, Wu P, Hou X, Ouyang J, Fan C, Li Z, Wang F, Guo C, Zhou M, Liao Q, et al. RNA modifications in cancer. Br J Cancer. 2023;129:204–21.
Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, Zhu X, Gu Y, Dominissini D, He L, Tian Y, Yi C, Fan Z. N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism. Nat Commun. 2021;12:6314.
Shi Q, Xue C, Yuan X, He Y, Yu Z. Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. Sci Rep. 2020;10:15083.
Zhao Y, Zhao Q, Kaboli PJ, Shen J, Li M, Wu X, et al. M1A regulated genes modulate PI3K/AKT/mTOR and erbb pathways in Gastrointestinal cancer. Transl Oncol. 2019;12:1323–33.
Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K, Hase H, Harada K, Hirata K, Tsujikawa K. AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017;7:42271.
Macari F, El-Houfi Y, Boldina G, Xu H, Khoury-Hanna S, Ollier J, Yazdani L, Zheng G, Bieche I, Legrand N, Paulet D, Durrieu S, et al. TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: impact on tumorigenesis. Oncogene. 2016;35:1785–96.
Gao Y, Wang H, Li H, Ye X, Xia Y, Yuan S, et al. Integrated analyses of m(1)A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer. Oncoimmunology. 2021;10:1936758.
Ma L, Zhu J, Zhang J, Zhang W, Li Y, Yang Z, et al. Identification of hepatoblastoma susceptibility loci in the TRMT6 gene from a seven-center case-control study. J Cell Mol Med. 2024;28:e18006.
Yang S, Yuan Y, Ren W, Wang H, Zhao Z, Zhao H, et al. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma. Front Oncol. 2022;12:1004324.
Yu M, Wang H, Xu H, Lv Y, Li Q. High MCM8 expression correlates with unfavorable prognosis and induces immune cell infiltration in hepatocellular carcinoma. Aging. 2022;14:10027–49.
Hao J, Deng H, Yang Y, Chen L, Wu Q, Yao P, Li J, Li B, Jin X, Wang H, Duan H. Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncol Rep. 2021;46:235.
Zheng Q, Yu X, Zhang Q, He Y, Guo W. Genetic characteristics and prognostic implications of m1A regulators in pancreatic cancer. Biosci Rep. 2021;41BSR20210337.
Archer NP, Perez-Andreu V, Scheurer ME, Rabin KR, Peckham-Gregory EC, Plon SE, et al. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in Hispanics. Cancer. 2016;122:3697–704.
Li Y, Zhou D, Liu Q, Zhu W, Ye Z, He C. Gene polymorphisms of m6A erasers FTO and ALKBH1 associated with susceptibility to gastric cancer. Pharmgenomics Pers Med. 2022;15:547–59.
Liao F, Hua RX, Jia X, Liao Y, Yuan L, Ruan J, Li T, Zhuo Z, He J. Association of m1A modification gene polymorphisms with glioma risk in Chinese children. MedComm – Oncol. 2023;2.
Ji Y, Liu Y, Sun C, Yu L, Wang Z, Du X, Yang W, Zhang C, Tao C, Wang J, Yang X, Di S, Huang Y. ADCK1 activates the beta-catenin/TCF signaling pathway to promote the growth and migration of colon cancer cells. Cell Death Dis. 2021;12:354.
Zhuo BB, Zhu LQ, Yao C, Wang XH, Li SX, Wang R, Li Y, Ling ZY. ADCK1 is a potential therapeutic target of osteosarcoma. Cell Death Dis. 2022;13:954.
Hong M, He J, Li S. SNW1 regulates Notch signaling in neuroblastoma through interacting with RBPJ. Biochem Biophys Res Commun. 2019;509:869–76.